JP2020510015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510015A5 JP2020510015A5 JP2019548449A JP2019548449A JP2020510015A5 JP 2020510015 A5 JP2020510015 A5 JP 2020510015A5 JP 2019548449 A JP2019548449 A JP 2019548449A JP 2019548449 A JP2019548449 A JP 2019548449A JP 2020510015 A5 JP2020510015 A5 JP 2020510015A5
- Authority
- JP
- Japan
- Prior art keywords
- lung
- compound
- pharmaceutically acceptable
- disease
- eosinophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 57
- 206010051604 Lung transplant rejection Diseases 0.000 claims description 32
- 208000023504 respiratory system disease Diseases 0.000 claims description 29
- 206010035664 Pneumonia Diseases 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 230000004064 dysfunction Effects 0.000 claims description 19
- 206010035742 Pneumonitis Diseases 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000002327 eosinophilic effect Effects 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- -1 2-ethyl-5-fluoro-4-hydroxyphenyl Chemical group 0.000 claims description 11
- 208000034706 Graft dysfunction Diseases 0.000 claims description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 11
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 230000000414 obstructive effect Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 206010006448 Bronchiolitis Diseases 0.000 claims description 6
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 208000027004 Eosinophilic disease Diseases 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 206010067472 Organising pneumonia Diseases 0.000 claims description 6
- 208000004530 Primary Graft Dysfunction Diseases 0.000 claims description 6
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 claims description 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 206010069351 acute lung injury Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 6
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 6
- 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- 230000000527 lymphocytic effect Effects 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims description 6
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 6
- 201000000306 sarcoidosis Diseases 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 201000009267 bronchiectasis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- WPQFPKRBWBVUHY-UHFFFAOYSA-N 5-ethyl-2-fluoro-4-(1H-indazol-6-yl)phenol Chemical compound CCC1=CC(=C(C=C1C2=CC3=C(C=C2)C=NN3)F)O WPQFPKRBWBVUHY-UHFFFAOYSA-N 0.000 claims description 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 0 CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CC(*)N(*)C3)c3[n]1)n[n]2 Chemical compound CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(CC(*)N(*)C3)c3[n]1)n[n]2 0.000 description 8
- LKYNKWVSJBBRNP-SANMLTNESA-N CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(C[C@@H](C(N(C3)CC3N(C)C)=O)N(C3)C(C)C)c3[nH]1)n[nH]2 Chemical compound CCc(cc(c(F)c1)O)c1-c(cc1)cc2c1c(-c1nc(C[C@@H](C(N(C3)CC3N(C)C)=O)N(C3)C(C)C)c3[nH]1)n[nH]2 LKYNKWVSJBBRNP-SANMLTNESA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469073P | 2017-03-09 | 2017-03-09 | |
| US62/469,073 | 2017-03-09 | ||
| PCT/US2018/021489 WO2018165392A1 (en) | 2017-03-09 | 2018-03-08 | Jak inhibitors containing a 4-membered heterocyclic amide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510015A JP2020510015A (ja) | 2020-04-02 |
| JP2020510015A5 true JP2020510015A5 (enExample) | 2021-04-01 |
| JP6974487B2 JP6974487B2 (ja) | 2021-12-01 |
Family
ID=61683956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548369A Active JP7134990B2 (ja) | 2017-03-09 | 2018-03-08 | 縮合イミダゾ－ピペリジンｊａｋ阻害剤 |
| JP2019548449A Active JP6974487B2 (ja) | 2017-03-09 | 2018-03-08 | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548369A Active JP7134990B2 (ja) | 2017-03-09 | 2018-03-08 | 縮合イミダゾ－ピペリジンｊａｋ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (10) | US10196393B2 (enExample) |
| EP (2) | EP3592742B1 (enExample) |
| JP (2) | JP7134990B2 (enExample) |
| KR (2) | KR102533646B1 (enExample) |
| CN (2) | CN110461839B (enExample) |
| AR (2) | AR111241A1 (enExample) |
| AU (2) | AU2018231035B2 (enExample) |
| BR (2) | BR112019018649A2 (enExample) |
| CA (1) | CA2997772A1 (enExample) |
| DK (1) | DK3592742T3 (enExample) |
| EA (2) | EA037748B1 (enExample) |
| ES (1) | ES2882186T3 (enExample) |
| IL (2) | IL268679B (enExample) |
| MX (2) | MX388749B (enExample) |
| PH (2) | PH12019501941A1 (enExample) |
| PT (1) | PT3592742T (enExample) |
| SG (2) | SG11201907544VA (enExample) |
| TW (2) | TWI754019B (enExample) |
| WO (2) | WO2018165392A1 (enExample) |
| ZA (2) | ZA201905585B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3371185B1 (en) * | 2015-11-03 | 2020-09-30 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| US10100049B2 (en) | 2015-11-03 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | JAK kinase inhibitor compounds for treatment of respiratory disease |
| CN110461839B (zh) | 2017-03-09 | 2022-08-23 | 施万生物制药研发Ip有限责任公司 | 含有4元杂环酰胺的jak抑制剂 |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| PL3837258T3 (pl) * | 2018-09-04 | 2024-09-16 | Theravance Biopharma R&D Ip, Llc | Amidy dimetyloaminoazetydyny jako inhibitory jak |
| EA202190686A1 (ru) | 2018-09-04 | 2021-07-23 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | 5-7-членные гетероциклические амиды в качестве ингибиторов jak |
| MX2021002273A (es) | 2018-09-04 | 2021-05-27 | Theravance Biopharma R&D Ip Llc | Proceso para preparar inhibidores de las jak y productos intermedios de estos. |
| AU2019373059A1 (en) | 2018-10-29 | 2021-05-06 | Theravance Biopharma R&D Ip, Llc | 2-azabicyclo hexane compound as JAK inhibitor |
| HRP20240994T1 (hr) | 2019-02-25 | 2024-10-25 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Spoj inhibitora jak i njegova uporaba |
| KR20210137087A (ko) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제 |
| WO2021108803A1 (en) * | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| WO2021136345A1 (zh) * | 2019-12-30 | 2021-07-08 | 路良 | Jak抑制剂化合物及其用途 |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022178215A1 (en) * | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CA3223194A1 (en) * | 2021-06-25 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Imidazolo indazole compounds as jak inhibitors |
| TWI876245B (zh) * | 2021-12-17 | 2025-03-11 | 南韓商大熊製藥股份有限公司 | (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形 |
| CN117658852A (zh) * | 2023-11-15 | 2024-03-08 | 西北工业大学 | 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用 |
| WO2025157904A1 (en) * | 2024-01-24 | 2025-07-31 | Kiox Pharmaceuticals Aps | Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof |
| CN118903009B (zh) * | 2024-10-11 | 2025-01-21 | 江苏长泰药业股份有限公司 | 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| JP5651681B2 (ja) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法 |
| CN102821607B (zh) | 2009-12-21 | 2014-12-17 | 萨穆梅德有限公司 | 1H-吡唑并[3，4-b]吡啶及其治疗应用 |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MA39092B1 (fr) | 2013-12-05 | 2018-09-28 | Pfizer | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides |
| SG11201609139WA (en) | 2014-05-14 | 2016-11-29 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| EP3371185B1 (en) * | 2015-11-03 | 2020-09-30 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| US10100049B2 (en) | 2015-11-03 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | JAK kinase inhibitor compounds for treatment of respiratory disease |
| CN110461839B (zh) | 2017-03-09 | 2022-08-23 | 施万生物制药研发Ip有限责任公司 | 含有4元杂环酰胺的jak抑制剂 |
| JP7096268B2 (ja) | 2017-05-01 | 2022-07-05 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤化合物の結晶形態 |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EA202190686A1 (ru) | 2018-09-04 | 2021-07-23 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | 5-7-членные гетероциклические амиды в качестве ингибиторов jak |
| PL3837258T3 (pl) | 2018-09-04 | 2024-09-16 | Theravance Biopharma R&D Ip, Llc | Amidy dimetyloaminoazetydyny jako inhibitory jak |
| MX2021002273A (es) | 2018-09-04 | 2021-05-27 | Theravance Biopharma R&D Ip Llc | Proceso para preparar inhibidores de las jak y productos intermedios de estos. |
-
2018
- 2018-03-08 CN CN201880017046.0A patent/CN110461839B/zh active Active
- 2018-03-08 KR KR1020197029543A patent/KR102533646B1/ko active Active
- 2018-03-08 WO PCT/US2018/021489 patent/WO2018165392A1/en not_active Ceased
- 2018-03-08 MX MX2019010539A patent/MX388749B/es unknown
- 2018-03-08 US US15/915,418 patent/US10196393B2/en active Active
- 2018-03-08 EP EP18711796.5A patent/EP3592742B1/en active Active
- 2018-03-08 ES ES18711796T patent/ES2882186T3/es active Active
- 2018-03-08 PT PT187117965T patent/PT3592742T/pt unknown
- 2018-03-08 SG SG11201907544VA patent/SG11201907544VA/en unknown
- 2018-03-08 AU AU2018231035A patent/AU2018231035B2/en not_active Ceased
- 2018-03-08 MX MX2019010541A patent/MX388750B/es unknown
- 2018-03-08 EA EA201992128A patent/EA037748B1/ru unknown
- 2018-03-08 WO PCT/US2018/021492 patent/WO2018165395A1/en not_active Ceased
- 2018-03-08 KR KR1020197029560A patent/KR102526764B1/ko active Active
- 2018-03-08 CN CN201880016693.XA patent/CN110382498B/zh not_active Expired - Fee Related
- 2018-03-08 AR ARP180100542A patent/AR111241A1/es not_active Application Discontinuation
- 2018-03-08 SG SG11201907840RA patent/SG11201907840RA/en unknown
- 2018-03-08 TW TW107107939A patent/TWI754019B/zh not_active IP Right Cessation
- 2018-03-08 EP EP18712398.9A patent/EP3592743A1/en not_active Withdrawn
- 2018-03-08 JP JP2019548369A patent/JP7134990B2/ja active Active
- 2018-03-08 TW TW107107936A patent/TWI779016B/zh not_active IP Right Cessation
- 2018-03-08 AU AU2018231032A patent/AU2018231032B2/en not_active Ceased
- 2018-03-08 US US15/915,434 patent/US10208040B2/en active Active
- 2018-03-08 JP JP2019548449A patent/JP6974487B2/ja active Active
- 2018-03-08 BR BR112019018649A patent/BR112019018649A2/pt not_active IP Right Cessation
- 2018-03-08 CA CA2997772A patent/CA2997772A1/en active Pending
- 2018-03-08 DK DK18711796.5T patent/DK3592742T3/da active
- 2018-03-08 EA EA201992126A patent/EA037261B1/ru not_active IP Right Cessation
- 2018-03-08 AR ARP180100543A patent/AR111242A1/es unknown
- 2018-03-08 BR BR112019018648-4A patent/BR112019018648A2/pt not_active IP Right Cessation
- 2018-12-17 US US16/222,647 patent/US10392386B2/en active Active
- 2018-12-19 US US16/225,473 patent/US10519153B2/en active Active
-
2019
- 2019-07-15 US US16/511,410 patent/US10550118B2/en active Active
- 2019-08-13 IL IL268679A patent/IL268679B/en unknown
- 2019-08-13 IL IL268689A patent/IL268689B2/en unknown
- 2019-08-22 PH PH12019501941A patent/PH12019501941A1/en unknown
- 2019-08-23 ZA ZA2019/05585A patent/ZA201905585B/en unknown
- 2019-08-26 ZA ZA2019/05618A patent/ZA201905618B/en unknown
- 2019-08-29 PH PH12019501985A patent/PH12019501985A1/en unknown
- 2019-11-11 US US16/679,676 patent/US11254669B2/en active Active
- 2019-12-03 US US16/701,426 patent/US10954237B2/en active Active
-
2021
- 2021-02-12 US US17/248,907 patent/US11453668B2/en active Active
-
2022
- 2022-01-14 US US17/576,089 patent/US11667637B2/en active Active
- 2022-08-10 US US17/885,475 patent/US11878977B2/en active Active